ReviewNeuropsychiatric disease and treatment2026
Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies.
Review in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke depression (PSD) is a common neuropsychiatric complication after stroke and has a substantial impact on functional recovery, quality of life, and long-term outcomes. Because stroke-related manifestations, including aphasia, cognitive impairment, fatigue, and somatic symptoms, overlap with depressive symptoms, the clinical identification of PSD still largely relies on symptom assessment and clinical interviews, resulting in delayed diagnosis and intervention in some patients. Recent studies indicate that the development of PSD is not driven by a single pathological process but involves multiple mechanisms, including neuroinflammation, neural network alterations, dysfunction of the neurovascular unit, disturbances in energy and lipid metabolism, imbalance of the microbiota-gut-brain axis, and psychosocial factors following brain injury. The advancement of multi-omics technologies has provided new approaches for investigating the biological mechanisms underlying PSD. This review systematically summarizes recent progress in the application of multi-omics approaches in PSD research, focusing on molecular alterations identified across different omics platforms and potential biomarkers. Furthermore, the role of the hypothalamic-pituitary-adrenal (HPA) axis in stress response regulation and PSD development is discussed within the context of neuro-immune-metabolic interactions. Overall, multi-omics studies have provided new insights into the molecular basis of PSD and facilitated the identification of potential biomarkers and therapeutic targets. However, their clinical utility requires further evaluation through standardized cohorts and validation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.